Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial (Portopulm)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
Tufts Medical Center
ClinicalTrials.gov Identifier:
NCT01224210
First received: October 18, 2010
Last updated: May 20, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)